awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q42279573-527C9264-DFC9-4BF3-992F-D1C44345B353
Q42279573-527C9264-DFC9-4BF3-992F-D1C44345B353
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42279573-527C9264-DFC9-4BF3-992F-D1C44345B353
Uncommon response of cisplatin and etoposide for treatment of advanced medullary thyroid carcinoma.
P2860
Q42279573-527C9264-DFC9-4BF3-992F-D1C44345B353
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42279573-527C9264-DFC9-4BF3-992F-D1C44345B353
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1eebbc34d8891de0007c2ed4137cc90ef12358bb
P2860
Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyr